Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study.J Clin Oncol. 2020; 38: 3418-3429
- Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study.J Clin Oncol. 2009; 27: 2328-2338
- Pediatric cancer mortality and survival in the United States, 2001-2016.Cancer. 2020; 126: 4379-4389
- The role of minimally invasive surgery in pediatric solid tumors.Pediatr Surg Int. 2015; 31: 213-228
- Ultrasound-guided core biopsy as the primary tool for tissue diagnosis in pediatric oncology.J Pediatr Hematol Oncol. 2014; 36: 333-336
- Percutaneous biopsy of pediatric solid tumors.Cancer. 2005; 104: 644-652
- Section E6.5-6.8 of the ACMG technical standards and guidelines: chromosome studies of lymph node and solid tumor-acquired chromosomal abnormalities.Genet Med. 2016; 18: 643-648
- Making the most of small samples: optimization of tissue allocation of pediatric solid tumors for clinical and research use.Pediatr Blood Cancer. 2020; 67https://doi.org/10.1002/pbc.28326
- Embryonal tumors of the central nervous system in children: the era of targeted therapeutics.Bioeng Basel Switz. 2018; 5: E78
- A Children’s Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.Nat Genet. 2017; 49: 1487-1494
- The landscape of genomic alterations across childhood cancers.Nature. 2018; 555: 321-327
- Comprehensive analysis of hypermutation in human cancer.Cell. 2017; 171: 1042-1056.e10
- Relevance of fusion genes in pediatric cancers: toward precision medicine.Mol Ther Nucleic Acids. 2017; 6: 315-326
- The genomic landscape of pediatric cancers: implications for diagnosis and treatment.Science. 2019; 363: 1170-1175
- Molecular alterations in pediatric solid tumors.Surg Pathol Clin. 2021; 14: 473-492
- Current state of pediatric sarcoma biology and opportunities for future discovery: a report from the sarcoma translational research workshop.Cancer Genet. 2016; 209: 182-194
- Recent progress in pediatric soft tissue sarcoma therapy.Semin Pediatr Surg. 2019; 28: 150862
- Systemic therapy in pediatric-type soft-tissue sarcoma.Curr Oncol. 2020; 27: 6-16
- MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.Mod Pathol. 2019; 32: 27-36
- Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition.JCO Precis Oncol. 2020; 4 (PO.19.00298)
- Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas.Cancer Cell. 2020; 37: 569-583.e5
- Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures.Oncologist. 2017; 22: 1478-1490
- Advances in the classification and treatment of pediatric brain tumors.Curr Opin Pediatr. 2021; 33: 26-32
- Childhood and adolescent cancer statistics, 2014.CA Cancer J Clin. 2014; 64: 83-103
- Genetic testing in the diagnosis and biology of acute leukemia.Am J Clin Pathol. 2019; 152: 322-346
- WHO classification of tumours of haematopoietic and lymphoid tissues.. 2011; 117: 5019-5032
- Gene rearrangement detection in pediatric leukemia.Clin Lab Med. 2021; 41: 551-561
- Acute lymphoblastic leukemia (Version 2.2021).(Available at:) (Accessed October 1, 2021)
- Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.N Engl J Med. 2014; 371: 1005-1015
- Clinical utility of custom-designed NGS panel testing in pediatric tumors.Genome Med. 2019; 11: 32
- Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.BMC Med Genomics. 2019; 12: 23
- Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.Genome Med. 2016; 8: 133
- A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen).Cold Spring Harb Mol Case Stud. 2019; 5: a004739
- The 2020 WHO classification: what’s new in soft tissue tumor Pathology?.Am J Surg Pathol. 2021; 45: e1-e23
- The 2021 WHO classification of tumors of the central nervous system: a summary.Neuro-Oncol. 2021; 23 (Available at:): 1231-1251
- Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.Lancet Oncol. 2017; 18: 958-971
- Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.Acta Neuropathol (Berl). 2016; 131: 821-831
- Advances in risk classification and treatment Strategies for Neuroblastoma.J Clin Oncol. 2015; 33: 3008-3017
- Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.Blood Adv. 2018; 2: 1449-1458
- Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001.Pediatr Blood Cancer. 2021; 68: e28719
- Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.Oncotarget. 2016; 7: 13886-13901
- Childhood acute lymphoblastic leukemia: progress through collaboration.J Clin Oncol. 2015; 33: 2938-2948
- Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies.Genet Med. 2019; 21: 2781-2790
- The landscape of pediatric precision oncology: program design, actionable alterations, and clinical trial development.Cancers. 2021; 13: 4324
- Larotrectinib: first global approval.Drugs. 2019; 79: 201-206
- Molecular characterization of inflammatory tumors facilitates initiation of effective therapy.Pediatrics. 2021; 148 (e2021050990)
- Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors.Nat Cancer. 2021; 2: 357-365
- Pediatric acute lymphoblastic leukemia.Haematologica. 2020; 105: 2524-2539
- Characteristics of pan-cancer patients with ultrahigh tumor mutation burden.Front Oncol. 2021; 11: 682017
- Avalanching mutations in biallelic mismatch repair deficiency syndrome.Nat Genet. 2015; 47: 194-196
- Lynch syndrome-associated colorectal cancer.N Engl J Med. 2018; 379: 764-773
- Survival benefit for individuals with constitutional mismatch repair deficiency undergoing Surveillance.J Clin Oncol. 2021; 39: 2779-2790
- Assessment of tumor mutational burden in pediatric tumors by real-life whole-exome sequencing and in Silico Simulation of targeted gene panels: how the choice of method could affect the clinical decision?.Cancers. 2020; 12: E230
- Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.Blood Adv. 2018; 2: 529-533
- DICER1 tumor predisposition.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2020: 1993-2022 (Available at:)
- Neurofibromatosis 1.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2022: 1993-2022 (Available at:)
- Neurofibromatosis 2.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2018: 1993-2022 (Available at:)
- Li-fraumeni syndrome.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2019: 1993-2022 (Available at:)
- Retinoblastoma.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2018: 1993-2022 (Available at:)
- Nevoid Basal cell carcinoma syndrome.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2018: 1993-2022 (Available at:)
- Lynch syndrome.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2021: 1993-2022 (Available at:)
- Hereditary Paraganglioma-Pheochromocytoma syndromes.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2018: 1993-2022 (Available at:)
- Tuberous Sclerosis complex.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2021: 1993-2022 (Available at:)
- Noonan syndrome.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2022: 1993-2022 (Available at:)
- Shwachman-diamond syndrome.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2018: 1993-2022 (Available at:)
- RUNX1 familial Platelet disorder with associated myeloid malignancies.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2021: 1993-2021 (Available at:)
- ETV6 thrombocytopenia and predisposition to leukemia.in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews® [Internet]. University of Washington, Seattle, Seattle (WA)2020: 1993-2021 (Available at:)
- Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.Cancer Discov. 2016; 6: 479-491
- Liquid biopsies: genotyping circulating tumor DNA.J Clin Oncol. 2014; 32: 579-586
- Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med. 2014; 6: 224ra24
- Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma.Nat Commun. 2020; 11: 5376
- A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium.Int J Cancer. 2019; 145: 1889-1901
- Clinically relevant and minimally invasive tumor Surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy.Clin Cancer Res. 2018; 24: 5850-5859
- A comprehensive circulating tumor DNA assay for detection of translocation and copy-number changes in pediatric sarcomas.Mol Cancer Ther. 2021; (MCT-20-0987): 1535-7163https://doi.org/10.1158/1535-7163.MCT-20-0987
- Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors.JCO Precis Oncol. 2018; : 1-13
Further reading
- Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.Nature Medicine. 2022; (In press)https://doi.org/10.1038/s41591-022-01856-6
Article info
Publication history
Published online: August 24, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
